Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.
Breccia
Massimo
M
Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it
De Cuia
Maria Rosaria
MR
D'Elia
Gianna Maria
GM
Francesca
Biondo
B
Mandelli
Franco
F
Alimena
Giuliana
G
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis; D011743:Pyrimidines / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000096:biosynthesis; D015398:Signal Transduction / Q000187:drug effects; D013737:Testis / Q000378:metabolism; D013739:Testosterone / Q000096:biosynthesis
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013739:Testosterone; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor